Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercepharma.com
FiercePharma
Get the latest updates from FiercePharma directly as they happen.
Follow now 352 followers
Latest posts
Last updated 1 day ago
Lilly's Zepbound scores 2nd approval with landmark FDA nod in obstructive sleep apnea
1 day ago
Thanks to a new FDA green light, Lilly’s dual GIP/GLP-1 blockbuster Zepbound...
Omnicom Health Group CEO McNally to step down amid Interpublic merger plans
1 day ago
On the heels of Omnicom’s announcement earlier this month that it’s acquiring...
Mirroring Merck's problem, GSK's Jemperli-Zejula study in ovarian cancer misses survival goal
1 day ago
Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may...
GoodRx Discusses the Evolving Healthcare Landscape and Industry Trends Shaping Patient Experience
1 day ago
Recently, Questex CEO, Paul Miller, sat down with GoodRx’s President and Chief...
Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod
1 day ago
Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas...
Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more
1 day ago
This week on "The Top Line," we bring you a special conversation...
A 'pivotal moment': Ionis enters next phase of commercial evolution with Tryngolza's FDA approval
1 day ago
With an FDA approval for Tryngolza (olezarsen) to treat the rare genetic...
Neurocrine's Crenessity ends 70-year drought with FDA nod for rare genetic disease
2 days ago
After seven decades with no advances in the treatment of the genetic...
Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles
2 days ago
The companies have "fulfilled all regulatory closing conditions" for the pending buyout...
Doctors weigh in on GLP-1s: The impact of celeb endorsements, the indications they’re hoping for and more
2 days ago
The ubiquity of GLP-1 agonists in popular culture may be negatively affecting...
FDA rejects J&J's subcutaneous Rybrevant filing and AZ's full approval bid for Andexxa
2 days ago
The FDA has sent complete response letters to Johnson & Johnson and...
After studies flag possible link between Novo's Ozempic and rare eye disorder, EU plans to investigate: Reuters
2 days ago
After the recent release of two independent studies suggested the use of...